Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials

Marie Rose B.S. Crombag; John B.A.G. Haanen; Paul Baas; Jos H. Beijnen; Alwin D.R. Huitema

doi:10.1016/j.jgo.2019.06.001

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials

Marie Rose B.S. Crombag, John B.A.G. Haanen, Paul Baas, Jos H. Beijnen, Alwin D.R. Huitema

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	529-532
Number of pages	4
Journal	Journal of Geriatric Oncology
Volume	11
Issue number	3
DOIs	https://doi.org/10.1016/j.jgo.2019.06.001
Publication status	Published - Apr 2020
Externally published	Yes

Access to Document

10.1016/j.jgo.2019.06.001

Cite this

@article{455250e7ade343d7aa69855259724090,

title = "Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials",

author = "Crombag, {Marie Rose B.S.} and Haanen, {John B.A.G.} and Paul Baas and Beijnen, {Jos H.} and Huitema, {Alwin D.R.}",

note = "Funding Information: Through John B.A.G. Haanen, NKI has received compensation for advisory roles from Amgen, AZ, Bayer, BMS, Celsius Therapeutics, Gadeta, GSK, Immunocore, Ipsen, MSD, Merck Serono, Neon Therapeutics, Novartis, Pfizer, Roche/Genentech, Seattle Genetics; and NKI has received grants from MSD, BMS, Novartis, and Neon Therapeutics. The other authors declare no conflict of interest in connection with this paper. ",

year = "2020",

month = apr,

doi = "10.1016/j.jgo.2019.06.001",

language = "English",

volume = "11",

pages = "529--532",

journal = "Journal of Geriatric Oncology",

issn = "1879-4068",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials

AU - Crombag, Marie Rose B.S.

AU - Haanen, John B.A.G.

AU - Baas, Paul

AU - Beijnen, Jos H.

AU - Huitema, Alwin D.R.

N1 - Funding Information: Through John B.A.G. Haanen, NKI has received compensation for advisory roles from Amgen, AZ, Bayer, BMS, Celsius Therapeutics, Gadeta, GSK, Immunocore, Ipsen, MSD, Merck Serono, Neon Therapeutics, Novartis, Pfizer, Roche/Genentech, Seattle Genetics; and NKI has received grants from MSD, BMS, Novartis, and Neon Therapeutics. The other authors declare no conflict of interest in connection with this paper.

PY - 2020/4

Y1 - 2020/4

UR - http://www.scopus.com/inward/record.url?scp=85081959575&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2019.06.001

DO - 10.1016/j.jgo.2019.06.001

M3 - Letter

C2 - 31208830

AN - SCOPUS:85081959575

SN - 1879-4068

VL - 11

SP - 529

EP - 532

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

IS - 3

ER -